Adicet Bio, Inc. (ACET)
$
6.47
-0.26 (-4.02%)
Key metrics
Financial statements
Free cash flow per share
-14.0733
Market cap
62.1 Million
Price to sales ratio
0
Debt to equity
0.0926
Current ratio
7.4742
Income quality
0.8154
Average inventory
0
ROE
-0.8296
Technology
Technology – consumer electronics
Largecap
With a market cap of 121,78 bil stock is ranked 1
Low risk
ISS score of this stock is ranked 1
Company description
Profile
Adicet Bio, Inc. is a biotechnology company focused on discovering and developing allogeneic gamma delta T cell therapies targeting cancer and other diseases. The operating expenses amount to $115,733,000.00 encompassing various operational costs incurred in the pursuit of advancing its innovative therapies. With an emphasis on engineered gamma delta T cells that integrate chimeric antigen receptors and T cell receptor-like antibodies, Adicet Bio enhances selective tumor targeting while facilitating both innate and adaptive anti-tumor immune responses. The EBITDA ratio is 0.00 highlighting the company's operational efficiency amid research and development efforts. Despite these advancements, the company reported a net loss of -$116,803,000.00 indicating challenges in its operations. Furthermore, the weighted average number of shares outstanding is 6,891,336.00 reflecting the company's shareholder base and financial structure. Adicet Bio's stock, identified with the symbol 'ACET' in the market, represents an investment opportunity in the biotechnology sector. Affordability is a key consideration for investors, as the stock is affordable at $0.79 making it suitable for budget-conscious investors. The stock has an average trading volume of 172,114.00 indicating moderate liquidity in the marketplace. With a market capitalization of $62,111,994.00 the company is classified as a small-cap player, which often attracts specific investment strategies. It is a key player in the Biotechnology industry, contributing significantly to the overall market landscape with its innovative approaches. Furthermore, it belongs to the Healthcare sector, driving innovation and growth through its targeted therapeutic developments. With its focus on advancing gamma delta T cell therapies and fostering a robust pipeline, Adicet Bio, Inc. stands as a noteworthy entity in the ongoing fight against cancer and other diseases while navigating the complexities of the biotech industry.
Is Adicet Bio, Inc. (ACET) a good investment?
Investing in Adicet Bio, Inc. (ACET) depends on multiple factors, including revenue growth, profit margins, debt-to-equity ratio, earnings per share, and return on equity. Analysts have rated it as B-, with a Bearish outlook. Always conduct your own research before investing.
What is Adicet Bio, Inc. (ACET)'s stock forecast?
Analysts predict Adicet Bio, Inc. stock to fluctuate between $6.41 (low) and $17.44 (high) in the next 365 days, reflecting market expectations and potential volatility.
What is Adicet Bio, Inc.'s market capitalization?
As of 2026-03-30, Adicet Bio, Inc.'s market cap is $62,111,994, based on 9,599,999 outstanding shares.
How does Adicet Bio, Inc. compare to competitors like Eli Lilly & Co.?
Compared to Eli Lilly & Co., Adicet Bio, Inc. has a Lower Market-Cap, indicating a difference in performance.
Does Adicet Bio, Inc. pay dividends?
Adicet Bio, Inc. pays dividends. The current dividend yield is 0.01%, with a payout of $0.00 per share.
How can I buy Adicet Bio, Inc. (ACET) stock?
To buy Adicet Bio, Inc. (ACET) stock: Open a brokerage account (e.g., Robinhood, TD Ameritrade, E-Trade). Search for ACET. Place an order (Market, Limit, etc.).
What is the best time to invest in Adicet Bio, Inc.?
The best time to invest depends on market trends and technical indicators, which show a Bearish trend based on economic conditions and company performance.
Has Adicet Bio, Inc. stock ever split?
Adicet Bio, Inc.'s last stock split was 1:16 on 2025-12-30.
How did Adicet Bio, Inc. perform in the last earnings report?
Revenue: $0 | EPS: -$16.95 | Growth: -20.35%.
Where can I find Adicet Bio, Inc.'s investor relations reports?
Visit https://www.adicetbio.com/investor-relations for detailed financial reports.
Where can I find historical stock prices for Adicet Bio, Inc.?
You can explore historical data from here
What is the all-time high and low for Adicet Bio, Inc. stock?
All-time high: $21.87 (2022-11-11) | All-time low: $0.45 (2025-04-10).
What are the key trends affecting Adicet Bio, Inc. stock?
Key trends include market demand, economic conditions, interest rates, and industry competition, which influence the stock's performance.
News
zacks.com
6 days ago
Adicet Bio (ACET) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
businesswire.com
18 days ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2025. “Adicet closed the year with solid momentum, driven by strong enrollment progress and the positive data from the prula-cel Phase 1 autoimmune study reported during the.
defenseworld.net
a month ago
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) has been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are currently covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell rating, one has given a hold rating, four have given a buy rating and one has
defenseworld.net
2 months ago
Shares of Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) have received a consensus rating of "Moderate Buy" from the seven research firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, one has assigned a hold rating, four have assigned a buy rating and one
businesswire.com
2 months ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today announced that Chen Schor, President and Chief Executive Officer, will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 being held from February 11-12, 2026 in New York. Details of the event are as follows: Date: Thursday, February 12, 2026 Time: 2:00p.m. ET The l.
defenseworld.net
2 months ago
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report)'s share price crossed below its two hundred day moving average during trading on Monday. The stock has a two hundred day moving average of $11.11 and traded as low as $7.87. Adicet Bio shares last traded at $8.28, with a volume of 137,944 shares. Analyst Upgrades
defenseworld.net
3 months ago
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) was the recipient of a significant decline in short interest during the month of December. As of December 31st, there was short interest totaling 642,724 shares, a decline of 95.7% from the December 15th total of 14,910,583 shares. Currently, 7.0% of the shares of the stock are
defenseworld.net
3 months ago
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) passed below its 200-day moving average during trading on Wednesday. The stock has a 200-day moving average of $11.22 and traded as low as $8.07. Adicet Bio shares last traded at $8.45, with a volume of 116,371 shares traded. Wall Street Analyst Weigh In Several research
businesswire.com
3 months ago
REDWOOD CITY, Calif.--(BUSINESS WIRE)--Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today provided corporate updates and highlighted upcoming milestones for 2026. “Heading into 2026, we are proud of the strong execution across our pipeline. Since reporting data in October from our prula-cel Phase 1 program in autoimmune diseases, enrollment has more than doubled with.
defenseworld.net
3 months ago
Adicet Bio, Inc. (NASDAQ: ACET - Get Free Report) was the recipient of a significant growth in short interest in the month of December. As of December 15th, there was short interest totaling 14,910,583 shares, a growth of 40.3% from the November 30th total of 10,629,486 shares. Based on an average daily trading volume, of 2,860,587
See all news
